Nasdaq · Common stock
Hemab Therapeutics Holdings (COAG)
$36.02 +$1.62 (+4.71%)
- Day’s range
- $34.39–$36.39
- Volume
- 269,191
COAG price history
COAG closed at $36.02 on Oct. 26, 2026. Over the past year, its daily close ranged from $24.98 on June 12, 2026 to $54.94 on Aug. 14, 2026.
Data table: COAG daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $36.02 |
| Oct. 23, 2026 | $34.40 |
| Oct. 22, 2026 | $34.82 |
| Oct. 21, 2026 | $35.34 |
| Oct. 20, 2026 | $34.17 |
| Oct. 19, 2026 | $32.09 |
| Oct. 16, 2026 | $30.07 |
| Oct. 15, 2026 | $32.52 |
| Oct. 14, 2026 | $29.94 |
| Oct. 13, 2026 | $29.80 |
| Oct. 12, 2026 | $30.39 |
| Oct. 9, 2026 | $31.62 |
| Oct. 8, 2026 | $30.89 |
| Oct. 7, 2026 | $28.70 |
| Oct. 6, 2026 | $28.37 |
| Oct. 5, 2026 | $30.59 |
| Oct. 2, 2026 | $31.11 |
| Oct. 1, 2026 | $31.06 |
| Sept. 30, 2026 | $30.84 |
| Sept. 29, 2026 | $32.60 |
| Sept. 28, 2026 | $33.12 |
| Sept. 25, 2026 | $34.74 |
| Sept. 24, 2026 | $35.72 |
| Sept. 23, 2026 | $36.73 |
| Sept. 22, 2026 | $38.25 |
| Sept. 21, 2026 | $37.97 |
| Sept. 18, 2026 | $41.19 |
| Sept. 17, 2026 | $41.22 |
| Sept. 16, 2026 | $40.97 |
| Sept. 15, 2026 | $40.11 |
| Sept. 14, 2026 | $40.47 |
| Sept. 11, 2026 | $39.40 |
| Sept. 10, 2026 | $39.88 |
| Sept. 9, 2026 | $44.50 |
| Sept. 8, 2026 | $44.57 |
| Sept. 4, 2026 | $44.41 |
| Sept. 3, 2026 | $44.37 |
| Sept. 2, 2026 | $44.70 |
| Sept. 1, 2026 | $44.02 |
| Aug. 31, 2026 | $45.73 |
| Aug. 28, 2026 | $44.84 |
| Aug. 27, 2026 | $49.49 |
| Aug. 26, 2026 | $49.19 |
| Aug. 25, 2026 | $49.65 |
| Aug. 24, 2026 | $46.67 |
| Aug. 21, 2026 | $49.16 |
| Aug. 20, 2026 | $48.20 |
| Aug. 19, 2026 | $51.66 |
| Aug. 18, 2026 | $52.44 |
| Aug. 17, 2026 | $53.59 |
| Aug. 14, 2026 | $54.94 |
| Aug. 13, 2026 | $53.95 |
| Aug. 12, 2026 | $53.48 |
| Aug. 11, 2026 | $51.74 |
| Aug. 10, 2026 | $49.87 |
| Aug. 7, 2026 | $49.66 |
| Aug. 6, 2026 | $52.16 |
| Aug. 5, 2026 | $50.09 |
| Aug. 4, 2026 | $46.52 |
| Aug. 3, 2026 | $45.00 |
| July 31, 2026 | $47.55 |
| July 30, 2026 | $47.47 |
| July 29, 2026 | $44.75 |
| July 28, 2026 | $47.26 |
| July 27, 2026 | $50.39 |
| July 24, 2026 | $47.31 |
| July 23, 2026 | $45.83 |
| July 22, 2026 | $49.23 |
| July 21, 2026 | $48.28 |
| July 20, 2026 | $49.39 |
| July 17, 2026 | $49.29 |
| July 16, 2026 | $44.53 |
| July 15, 2026 | $43.32 |
| July 14, 2026 | $43.31 |
| July 13, 2026 | $39.51 |
| July 10, 2026 | $38.03 |
| July 9, 2026 | $37.20 |
| July 8, 2026 | $33.89 |
| July 7, 2026 | $31.49 |
| July 6, 2026 | $29.97 |
| July 2, 2026 | $31.00 |
| July 1, 2026 | $32.50 |
| June 30, 2026 | $36.73 |
| June 29, 2026 | $36.73 |
| June 26, 2026 | $32.37 |
| June 25, 2026 | $27.72 |
| June 24, 2026 | $28.76 |
| June 23, 2026 | $29.15 |
| June 22, 2026 | $31.74 |
| June 18, 2026 | $29.24 |
| June 17, 2026 | $26.45 |
| June 16, 2026 | $25.51 |
| June 15, 2026 | $25.08 |
| June 12, 2026 | $24.98 |
| June 11, 2026 | $26.94 |
| June 10, 2026 | $25.55 |
| June 9, 2026 | $27.00 |
| June 8, 2026 | $25.55 |
| June 5, 2026 | $25.30 |
| June 4, 2026 | $25.41 |
| June 3, 2026 | $26.17 |
| June 2, 2026 | $27.47 |
| June 1, 2026 | $27.13 |
| May 29, 2026 | $28.50 |
| May 28, 2026 | $28.00 |
| May 27, 2026 | $28.60 |
| May 26, 2026 | $27.84 |
| May 22, 2026 | $25.89 |
| May 21, 2026 | $26.30 |
| May 20, 2026 | $26.47 |
| May 19, 2026 | $25.44 |
| May 18, 2026 | $27.15 |
| May 15, 2026 | $28.07 |
| May 14, 2026 | $28.37 |
| May 13, 2026 | $28.56 |
| May 12, 2026 | $25.90 |
| May 11, 2026 | $25.00 |
| May 8, 2026 | $25.12 |
| May 7, 2026 | $25.74 |
| May 6, 2026 | $25.01 |
| May 5, 2026 | $25.00 |
| May 4, 2026 | $25.34 |
| May 1, 2026 | $34.00 |
Key figures
- Average daily volume
- 451,066Past 3 months
- Market value
- $1.68B
- Dividend yield
- —
Price change
- 1 month
- +3.68%
- 3 months
- −23.86%
What Wall Street says about COAG
In the past 90 days, Wall Street firms published 4 rating or price-target actions on COAG: 2 new ratings and 2 raised price targets.
| Action | Rating | |||
|---|---|---|---|---|
| JP Morgan | Initiates coverage | Overweight | $70 | |
| Rodman & Renshaw | Initiates coverage | Buy | $56 | |
| Wedbush | Raises target | Outperform | $55 to $64 | |
| HC Wainwright & Co. | Raises target | Buy | $52 to $60 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
- Headquarters
- Cambridge, Mass.
- Listed
- May 1, 2026
- Sector
- Health care
- Industry
- Biological products, (no diagnostic substances)
In WallStreetDigest editions
No WallStreetDigest article about COAG is on the site yet.